Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Early mobilisation in critically ill COVID-19 patients: a subanalysis of the ESICM-initiated UNITE-COVID observational study

Background Early mobilisation (EM) is an intervention that may improve the outcome of critically ill patients. There is limited data on EM in COVID-19 patients and its use during the first pandemic wave. Methods This is a pre-planned subanalysis of the ESICM UNITE-COVID, an international multicenter observational study involving critically ill COVID-19 patients in the ICU between February 15th and May 15th, 2020. We analysed variables associated with the initiation of EM (within 72 h of ICU admission) and explored the impact of EM on mortality, ICU and hospital length of stay, as well as discharge location. Statistical analyses were done using (generalised) linear mixed-effect models and ANOVAs. Results Mobilisation data from 4190 patients from 280 ICUs in 45 countries were analysed. 1114 (26.6%) of these patients received mobilisation within 72 h after ICU admission; 3076 (73.4%) did not. In our analysis of factors associated with EM, mechanical ventilation at admission (OR 0.29; 95% CI 0.25, 0.35; p = 0.001), higher age (OR 0.99; 95% CI 0.98, 1.00; p ≤ 0.001), pre-existing asthma (OR 0.84; 95% CI 0.73, 0.98; p = 0.028), and pre-existing kidney disease (OR 0.84; 95% CI 0.71, 0.99; p = 0.036) were negatively associated with the initiation of EM. EM was associated with a higher chance of being discharged home (OR 1.31; 95% CI 1.08, 1.58; p = 0.007) but was not associated with length of stay in ICU (adj. difference 0.91 days; 95% CI − 0.47, 1.37, p = 0.34) and hospital (adj. difference 1.4 days; 95% CI − 0.62, 2.35, p = 0.24) or mortality (OR 0.88; 95% CI 0.7, 1.09, p = 0.24) when adjusted for covariates. Conclusions Our findings demonstrate that a quarter of COVID-19 patients received EM. There was no association found between EM in COVID-19 patients' ICU and hospital length of stay or mortality. However, EM in COVID-19 patients was associated with increased odds of being discharged home rather than to a care facility. Trial registration ClinicalTrials.gov: NCT04836065 (retrospectively registered April 8th 2021)

Fresh versus frozen embryo transfer in women with polycystic ovaries syndrome undergoing in vitro fertilisation

Abstract Background Polycystic ovarian syndrome (PCOS) cases undergoing in vitro fertilisation (IVF) are widely at risk of ovarian hyperstimulation; therefore, elective freezing of all embryos to be transferred in a later cycle is preferred. We aimed to compare the pregnancy outcome between the fresh and the frozen embryo transfer (ET) in PCOS cases undergoing IVF with antagonist ovarian induction using human chorionic gonadotropin (HCG) as a trigger. Methods In this prospective randomised study, 110 infertile PCOS women underwent fresh ET (group A) or frozen ET (group B) with GnRH-antagonist protocol. The primary outcome was the chemical and clinical pregnancy rates. The secondary outcomes were the ongoing pregnancy rate, ovarian hyperstimulation syndrome (OHSS) rate, pregnancy loss rate, ectopic pregnancy rate, and congenital anomalies rate. Results There was no significant difference between both groups regarding chemical pregnancy rate (44.23% vs 47.27%, P = 0.752), clinical pregnancy rate (42.31% vs 43.64%, P = 0.89), ongoing pregnancy rate (38.46% vs 41.82%, P = 0.723), pregnancy loss rate (17.39% vs 15.4%, P = 1), ectopic pregnancy rate (1.92% vs 0%, P = 0.486) and anomaly malformation rate (4.35% vs 3.85%, P = 1). On the other hand, the incidence of OHSS was significantly less in group B than in group A (3.64% vs 19.23%, P = 0.011), and the OHSS grade was less severe in group B than in group A (P = 0.033). However, there was no statistically significant difference between both regarding the need for hospitalisation (P = 0.111), ICU admission (P = 0.486), and ascites tapping (P = 0.486). Conclusions Under GnRH-antagonist protocol, frozen ET has the upper hand in PCOS undergoing IVF treatment for infertility, as it protects against OHSS and decreases its severity. Trial registration It was first registered at ClinicalTrials.gov on 22/12/2021 with registration number NCT05167838

sj-tiff-2-han-10.1177_15589447221130093 – Supplemental material for Virtual and Augmented Reality in Management of Phantom Limb Pain: A Systematic Review

Supplemental material, sj-tiff-2-han-10.1177_15589447221130093 for Virtual and Augmented Reality in Management of Phantom Limb Pain: A Systematic Review by Abdullah S. Eldaly, Francisco R. Avila, Ricardo A. Torres-Guzman, Karla C. Maita, John P. Garcia, Luiza Palmieri Serrano, Omar S. Emam and Antonio J. Forte in HAND</p

sj-docx-1-han-10.1177_15589447221130093 – Supplemental material for Virtual and Augmented Reality in Management of Phantom Limb Pain: A Systematic Review

Supplemental material, sj-docx-1-han-10.1177_15589447221130093 for Virtual and Augmented Reality in Management of Phantom Limb Pain: A Systematic Review by Abdullah S. Eldaly, Francisco R. Avila, Ricardo A. Torres-Guzman, Karla C. Maita, John P. Garcia, Luiza Palmieri Serrano, Omar S. Emam and Antonio J. Forte in HAND</p

Supplemental Material - Machine Learning Algorithms Predict Long-Term Postoperative Opioid Misuse: A Systematic Review

Supplemental Material for Machine Learning Algorithms Predict Long-Term Postoperative Opioid Misuse: A Systematic Review by Omar S. Emam, Abdullah S. Eldaly, Francisco R. Avila, Ricardo A. Torres-Guzman, Karla C. Maita, John P. Garcia, Sally Anne Brown, Clifton R Haider, and Antonio J. Forte in The American Surgeon™.</p

Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study

OBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally

Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set

Background: The COVID-19 pandemic presented major challenges for critical care facilities worldwide. Infections which develop alongside or subsequent to viral pneumonitis are a challenge under sporadic and pandemic conditions; however, data have suggested that patterns of these differ between COVID-19 and other viral pneumonitides. This secondary analysis aimed to explore patterns of co-infection and intensive care unit-acquired infections (ICU-AI) and the relationship to use of corticosteroids in a large, international cohort of critically ill COVID-19 patients.Methods: This is a multicenter, international, observational study, including adult patients with PCR-confirmed COVID-19 diagnosis admitted to ICUs at the peak of wave one of COVID-19 (February 15th to May 15th, 2020). Data collected included investigator-assessed co-infection at ICU admission, infection acquired in ICU, infection with multi-drug resistant organisms (MDRO) and antibiotic use. Frequencies were compared by Pearson's Chi-squared and continuous variables by Mann-Whitney U test. Propensity score matching for variables associated with ICU-acquired infection was undertaken using R library MatchIT using the "full" matching method.Results: Data were available from 4994 patients. Bacterial co-infection at admission was detected in 716 patients (14%), whilst 85% of patients received antibiotics at that stage. ICU-AI developed in 2715 (54%). The most common ICU-AI was bacterial pneumonia (44% of infections), whilst 9% of patients developed fungal pneumonia; 25% of infections involved MDRO. Patients developing infections in ICU had greater antimicrobial exposure than those without such infections. Incident density (ICU-AI per 1000 ICU days) was in considerable excess of reports from pre-pandemic surveillance. Corticosteroid use was heterogenous between ICUs. In univariate analysis, 58% of patients receiving corticosteroids and 43% of those not receiving steroids developed ICU-AI. Adjusting for potential confounders in the propensity-matched cohort, 71% of patients receiving corticosteroids developed ICU-AI vs 52% of those not receiving corticosteroids. Duration of corticosteroid therapy was also associated with development of ICU-AI and infection with an MDRO.Conclusions: In patients with severe COVID-19 in the first wave, co-infection at admission to ICU was relatively rare but antibiotic use was in substantial excess to that indication. ICU-AI were common and were significantly associated with use of corticosteroids